JP2014515408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515408A5 JP2014515408A5 JP2014513795A JP2014513795A JP2014515408A5 JP 2014515408 A5 JP2014515408 A5 JP 2014515408A5 JP 2014513795 A JP2014513795 A JP 2014513795A JP 2014513795 A JP2014513795 A JP 2014513795A JP 2014515408 A5 JP2014515408 A5 JP 2014515408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- bipolar disorder
- inositol
- scyllo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000020925 Bipolar disease Diseases 0.000 claims 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 206010026749 Mania Diseases 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 229960000367 inositol Drugs 0.000 claims 4
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010021030 Hypomania Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 229940084026 sodium valproate Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520031P | 2011-06-03 | 2011-06-03 | |
| US61/520,031 | 2011-06-03 | ||
| US201161541333P | 2011-09-30 | 2011-09-30 | |
| US61/541,333 | 2011-09-30 | ||
| US201261618680P | 2012-03-31 | 2012-03-31 | |
| US61/618,680 | 2012-03-31 | ||
| PCT/US2012/040789 WO2012173808A1 (en) | 2011-06-03 | 2012-06-04 | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515408A JP2014515408A (ja) | 2014-06-30 |
| JP2014515408A5 true JP2014515408A5 (OSRAM) | 2015-07-23 |
Family
ID=46298680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513795A Pending JP2014515408A (ja) | 2011-06-03 | 2012-06-04 | 行動及び精神障害の治療のためのシロ−イノシトール |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140243422A1 (OSRAM) |
| EP (1) | EP2714050A1 (OSRAM) |
| JP (1) | JP2014515408A (OSRAM) |
| KR (1) | KR20140041670A (OSRAM) |
| CN (1) | CN103906520A (OSRAM) |
| AU (1) | AU2012271068A1 (OSRAM) |
| BR (1) | BR112013031117A8 (OSRAM) |
| CA (1) | CA2837926A1 (OSRAM) |
| IL (1) | IL229658A0 (OSRAM) |
| RU (1) | RU2013154699A (OSRAM) |
| WO (1) | WO2012173808A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2014110277A1 (en) * | 2013-01-09 | 2014-07-17 | Elan Pharmaceuticals, Inc. | Methods of treating developmental and personality disorders |
| US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
| WO2017004226A1 (en) * | 2015-06-30 | 2017-01-05 | Jds Therepeutics, Llc | Arginine silicate inositol for improving cognitive function |
| WO2017029353A1 (en) * | 2015-08-20 | 2017-02-23 | Transition Therapeutics Ireland Limited | Treatment of behaviors in dementia patients |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| CN109890384A (zh) | 2016-09-01 | 2019-06-14 | Jds治疗有限公司 | 生物素镁组合物和使用方法 |
| MX2021005213A (es) | 2018-11-02 | 2021-09-08 | Nutrition 21 Llc | Composiciones que contienen complejos de silicato de arginina estabilizado con inositol y inositol para mejorar funciones cognitivas en jugadores de videojuegos. |
| MX2022006535A (es) * | 2019-12-02 | 2022-09-09 | Suven Life Sciences Ltd | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
| PL4069231T3 (pl) * | 2019-12-02 | 2025-09-08 | Suven Life Sciences Limited | Połączenia masupirdyny z donepezilem lub memantyną do leczenia obajwów behawioralnych i psychologicznych u pacjentów z demencją |
| IL294021A (en) | 2019-12-16 | 2022-08-01 | Nutrition 21 Llc | Methods of production of arginine-silicate complexes |
| JP2025530588A (ja) * | 2022-09-07 | 2025-09-16 | エアジェン ファーマ リミテッド | Ｓｃｙｌｌｏ－イノシトールとフラボンとの組み合わせ |
| CN115998724B (zh) * | 2023-03-28 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 布洛芬在抗幻觉作用药物中的新用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| IL156203A0 (en) * | 2003-05-29 | 2003-12-23 | Yissum Res Dev Co | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| DK2058390T3 (da) | 2003-10-14 | 2013-05-06 | Hokko Chem Ind Co | Fremgangsmåde til fremstilling af scyllo-inositol |
| ZA200807993B (en) * | 2006-03-09 | 2010-02-24 | Waratah Pharmaceuticals Inc | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| CA2644804A1 (en) * | 2006-03-09 | 2007-09-13 | Waratah Pharmaceuticals Inc. | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| EP2545023A4 (en) | 2010-02-15 | 2017-04-12 | Abbvie Inc. | Process for the preparation of scyllo-inositol |
| US20150306043A1 (en) * | 2012-09-28 | 2015-10-29 | Transition Therapeutics Ireland Limited | Combination treatments for bipolar disorders |
-
2012
- 2012-06-04 CA CA2837926A patent/CA2837926A1/en not_active Abandoned
- 2012-06-04 WO PCT/US2012/040789 patent/WO2012173808A1/en not_active Ceased
- 2012-06-04 RU RU2013154699/15A patent/RU2013154699A/ru not_active Application Discontinuation
- 2012-06-04 AU AU2012271068A patent/AU2012271068A1/en not_active Abandoned
- 2012-06-04 CN CN201280037339.8A patent/CN103906520A/zh active Pending
- 2012-06-04 KR KR1020147000006A patent/KR20140041670A/ko not_active Withdrawn
- 2012-06-04 JP JP2014513795A patent/JP2014515408A/ja active Pending
- 2012-06-04 BR BR112013031117A patent/BR112013031117A8/pt not_active IP Right Cessation
- 2012-06-04 EP EP12727719.2A patent/EP2714050A1/en not_active Withdrawn
- 2012-06-04 US US14/123,581 patent/US20140243422A1/en not_active Abandoned
-
2013
- 2013-11-27 IL IL229658A patent/IL229658A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515408A5 (OSRAM) | ||
| CA2923685C (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2017510607A5 (OSRAM) | ||
| JP2015524444A5 (OSRAM) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2012524112A5 (OSRAM) | ||
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| JP2010513250A5 (OSRAM) | ||
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| MX390101B (es) | Tratamiento medico que comprende administracion enteral de edaravona | |
| JP2016505050A5 (OSRAM) | ||
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| BR112014004339A2 (pt) | suspensão oral | |
| RS59496B1 (sr) | Farmaceutska kompozicija za upotrebu u povećanju trofizma sluznice nosa | |
| JP2016504361A5 (OSRAM) | ||
| JP7335954B2 (ja) | 白頭翁サポニンｂ４の抗急性痛風性関節炎の医薬における用途 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |